Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE HealthCare Technologies Inc

Recursion is a clinical-stage biotech that is benefiting from big-time partnerships. GE Healthcare has AI algorithms built into the software with its imaging and diagnostic systems.

2 Healthcare AI Stocks That Could Go Parabolic

Valence Labs is Recursion's new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships. Valence Labs is Recursion's new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

Schrodinger 

Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.

Biotech Stocks Join AI-Fueled Rally

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.

3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other

Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

The artificial intelligence (AI) trade has been blistering higher, but Wednesday featured an interesting surge. That's as shares of Recursion Pharmaceuticals (NASDAQ: RXRX ) are exploding higher on the day.

Did Nvidia Just Trigger a Short Squeeze in RXRX Stock?

Schrödinger and Recursion Pharmaceuticals use AI to improve drug development. Neither one has proven its business model to be viable yet.

Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals

NVIDIA just announced an investment in Recursion Pharmaceuticals. Recursion still may not have a medicine out the door for a while.

NVIDIA Just Invested $50 Million in This Biotech -- Should You Buy It?

Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used to construct and navigate vast datasets, enabling the identification of patterns in the data that would be impossible for humans to detect. Despite significant revenue growth, Recursion's ability to generate revenue is still very hard to predict, and therefore the dilution risk looms large for shareholders.

Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint

Blueprint Medicines

ExScientia Ltd

The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE: MDT ) led the way, partnering with tech giants such as Nvidia (NASDAQ: NVDA ), to develop AI-powered solutions to medical problems.

3 Biotech Stocks Using AI to Change Healthcare Forever

NVIDIA

Nvidia is investing $50 million in Recursion Pharmaceuticals. The two companies are also working together to use AI to speed up drug discovery.

Why Recursion Pharmaceuticals Stock Is Skyrocketing This Week (Hint: Thanks, Nvidia)

Recursion Pharmaceuticals (NASDAQ: RXRX ) stock is the talk of Wall Street lately. Indeed, RXRX soared more than 120% Wednesday after Nvidia (NASDAQ: NVDA ) announced it would invest $50 million into the biotech firm to use artificial intelligence (AI) for drug discovery.

Did Nvidia Make Recursion Pharmaceuticals (RXRX) Stock the Next AI Play?

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

Tech giant NVIDIA Corporation (NASDAQ:NVDA) has dedicated US$50mln to a multi-year collaboration with US-listed biotech company Recursion Pharmaceuticals to develop AI-based software for improving patient treatments.  Recursion also announced plans to accelerate the development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimise and distribute to biotechnology companies using NVIDIA cloud services.

Nvidia and Recursion Pharmaceuticals team up on AI-based biotech collaboration

Nvidia's investment in Recursion caused its stock price to jump dramatically on Tuesday.

Nvidia Just Invested in This Pharmaceutical Company, Causing Its Stock Price to Skyrocket

Confirming the ongoing fervor for all things artificial intelligence (AI), shares of biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX ) are soaring on Wednesday. What has catalyzed the massive double-digit swing for RXRX stock?

RXRX Stock: Nvidia Investment Sends Recursion Pharmaceuticals Soaring

Recursion Pharmaceuticals stock soared as much as 121% on Wednesday after it received an investment from Nvidia. Nvidia said it would invest $50 million in the company as it works to use AI for drug discovery.

Recursion Pharmaceuticals soars 121% after Nvidia invests $50 million in the biotech for AI drug discovery

Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners, including Roche and Bayer.

Nvidia invests $50 million in biotech company Recursion for AI drug discovery

Recursion Pharmaceuticals Inc. RXRX, +75.96% shares soared Wednesday after the drug developer said that graphics processing unit maker Nvidia Corp. NVDA, +2.54% invested $50 million in the company to boost drug discovery efforts using artificial intelligence. Recursion shares surged as much as 120% to an intraday high of $14.99, and were last up 64% at $11.11 in morning trading.

Recursion Pharmaceuticals stock soars following $50 million investment from AI chipmaker Nvidia

Recursion focuses on drug discovery through machine learning. The company has nine programs in its pipeline.

Why Shares of Recursion Pharmaceuticals Are Skyrocketing Wednesday

Recursion Pharmaceuticals Inc shares surged 64% to $11.09 in late-morning trading on Wednesday after NVIDIA Corp announced it is making a $50 million investment to accelerate training of the biotech company's artificial intelligence (AI) models for drug discovery. Recursion stated that it will train AI models on NVIDIA's cloud platform using its own biological and chemical datasets exceeding 23,000 terabytes, which it can then potentially license out to biotech firms via BioNeMo, a generative AI cloud service for drug discovery that NVIDIA launched earlier this year, Reuters reported.

Recursion Pharmaceuticals stock soars on NVIDIA investment in AI

Recursion Pharmaceuticals stock has gained more than 150%.

Nvidia Invests $50 Million in Biotech Company For AI Drug Discovery

Nvidia invested $50 million to speed up training of biotech firm Recursion's artificial intelligence models for drug discovery, which the chip designer can then potentially license out, the companies said on Wednesday.

Nvidia invests $50 mln in Recursion to train AI models for drug discovery

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

AbCellera Biologics

Veracyte

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.

News for Recursion Pharmaceuticals Stock (RXRX)